American College Of Rheumatology 2024. Attend the world’s premier rheumatology event in washington, d.c.: Acr convergence 2024 is the world’s premier rheumatology meeting.
New phase 2b study results for zasocitinib, an investigational oral selective tyrosine kinase 2 (tyk2) inhibitor, will be presented at the american college of rheumatology (acr). An engaging mix of new and returning programming is planned for acr.
American College Of Rheumatology 2024 Images References :